Bilateral Retromuscular Rectus Sheath Block Catheters Usage for Early Postoperative Analgesia After Laparotomic Gastrectomy.
1 other identifier
interventional
100
1 country
2
Brief Summary
In early postoperative period, the occurrence of severe pain after open major upper GI surgery is a significant issue. The study is aimed to access the efficiency of rectus sheet block with continuous bupivacaine infusion catheters into retromuscular space in providing an effective pain relief, decreasing opioid consumption and enhancing postoperative recovery.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable postoperative-pain
Started Jan 2021
Longer than P75 for not_applicable postoperative-pain
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2021
CompletedFirst Submitted
Initial submission to the registry
October 6, 2022
CompletedFirst Posted
Study publicly available on registry
October 24, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
January 31, 2024
CompletedOctober 24, 2022
October 1, 2022
3 years
October 6, 2022
October 20, 2022
Conditions
Outcome Measures
Primary Outcomes (2)
Pain scores
Patients will be asked to score their pain in recovery and on days 0,1,2,3 post surgery
3 days
Opioid usage after surgery
If the VAS of pains is more than 30mm, after receiving NSAIDs, opioid solution will be performed
3 days
Secondary Outcomes (4)
Peri-operative analgesic use
4 days
TIme to diet and mobilisation
likely 5 days
Time to discharge
approximately 7 days
Postoperative complications
approximately 14 days
Study Arms (2)
Block group
ACTIVE COMPARATORPatients after laparotomic gastrectomy and musculus rectus sheath block and continuous analgesia with 0,125% bupivacaine solution for 72h
Control group
PLACEBO COMPARATORPatients after laparotomic gastrectomy, musculus rectus sheath block and induction of 0,9% NaCl Solution by using "easy pump" system for 72 h
Interventions
After surgery patients in the Block group receives continuous 0.125% (10-12 mg/h) bupivacaine infusion through rectus sheath catheters for 72 h in addition to fentanyl i/v infusion on postoperative day 0, and ketorolac or trimeperidine injection on postoperative day 1-2 if necessery. Patients in the Control group receives NaCl 0,9% infusion and fentanyl i/v infusion on postoperative day 0 and ketorolac or trimeperidine injection on postoperative day 1-2 if necessery Pain intensity is going to be assessed in both groups using 0-100 mm Visual Analog Scale (VAS) at 24, 48 and 72 hour intervals after surgery at rest and during movement (by asking the patient to bend legs). Postoperative complications, hospital stay, comorbidities, the time taken to start walking after the surgery, bowel movements (time until first stool) were all examined.
By using special tube, it is possible to locate the catheters in retromuscular space, where they are close to cutaneous nervs
Connection of catheters, which are inserted in to retromuscular space, to ensure continuous receiving of Bupivacaine fluid for analgesia. "Easy pump" system provides continous receiving of bupivacaine fluid infusion speed - 5ml per hour
By using Visual Analog scale of pains, the pain score is fixed
Eligibility Criteria
You may qualify if:
- Open Laparotomy and gastrectomy
You may not qualify if:
- acute surgery
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Riga East Clinical University Hospitallead
- University of Latviacollaborator
Study Sites (2)
Igors Ivanovs
Riga, LV1038, Latvia
Riga East Clinical University hospital
Riga, LV1038, Latvia
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- PARTICIPANT
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER GOV
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
October 6, 2022
First Posted
October 24, 2022
Study Start
January 1, 2021
Primary Completion
December 31, 2023
Study Completion
January 31, 2024
Last Updated
October 24, 2022
Record last verified: 2022-10